Assembly Biosciences (ASMB) EBT (2010 - 2026)

Assembly Biosciences' EBT history runs 17 years deep, the most recent figure standing at -$11.7 million for Q1 2026.

• On a quarterly basis, EBT fell 17.17% year-over-year to -$11.7 million in Q1 2026; TTM through Mar 2026 was -$9.0 million, a 77.91% increase from a year earlier, with the FY2025 full-year figure at -$6.1 million, up 84.64% from the prior year.
• EBT fell to -$11.7 million in Q1 2026 per ASMB's latest filing, from $22.1 million in the prior quarter.
• Across five years, EBT topped out at $22.1 million in Q4 2025 and bottomed at -$24.7 million in Q2 2022.
• The 5-year median for EBT is -$10.9 million (2023), against an average of -$12.7 million.
• Across the five-year window, EBT soared 312.18% in 2025 and dropped 17.17% in 2026, its largest moves.
• Year by year, EBT stood at -$24.2 million in 2022, then soared by 54.75% to -$10.9 million in 2023, then rose by 4.74% to -$10.4 million in 2024, then jumped by 312.18% to $22.1 million in 2025, then plunged by 152.95% to -$11.7 million in 2026.
• Per Business Quant, the three latest ASMB EBT figures stand at -$11.7 million (Q1 2026), $22.1 million (Q4 2025), and -$9.2 million (Q3 2025).